The first ASX share that Bell Potter is tipping as a buy is Clinuvel. It is a pharmaceutical company distributing its lead drug Scenesse (afamelanotide) across Europe and the USA for patients with the rare disease Erythropoietic protoporphyria (EPP).Bell Potter believes that its shares are good value given its strong growth outlook. This is being underpinned by its existing EPP product and its potential expansion into other areas.
Trading at approximately 7.4x EV/EBITDA valuations are not stretched, our analysts view the current valuation as well-supported by its existing, highly profitable EPP franchise alone without consideration for the substantial market opportunity presented by its vitiligo treatment program.
CUV Price at posting:
$12.28 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)